Skip to main content
Erschienen in: Annals of Hematology 12/2016

21.09.2016 | Original Article

Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel)

verfasst von: Chiara Cattaneo, P. Zappasodi, V. Mancini, C. Annaloro, F. Pavesi, C. Skert, A. Ferrario, E. Todisco, V. Saccà, L. Verga, A. Passi, M. Da Vià, S. Ferrari, G. Mometto, M. Petullà, A. Nosari, G. Rossi

Erschienen in: Annals of Hematology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Multiresistant bacterial infections are a potentially life-threatening condition in acute leukaemia (AL) patients. We aimed to better define the very recent epidemiology and outcome of bloodstream infections (BSIs) in a real-life setting. We prospectively collected all consecutive febrile/infectious episodes occurring in AL patients admitted to 9 haematology units. In 293 AL patients, 433 BSIs were diagnosed. Gram-positive (GP) bacteria were isolated in 44.8 % BSI and Gram-negative (GN) in 38.3 %, while polymicrobial aetiology- or fungi-related events were identified in 15.7 and 1.1 % of the cases, respectively. GP was observed more frequently in patients not in complete remission (p = 0.04), while GN during consolidation cycles (p = 0.003). Extended spectrum β-lactamase-producing strains accounted for 23.2 % of enterobacteria. They were associated with previous antibiotic exposure, including fluoroquinolones prophylaxis (p = 0.01). Carbapenem-resistant (CR) strains occurred in 9 % of enterobacteria. Among Pseudomonas aeruginosa strains, 21.6 % were multiresistant. Overall 30-day mortality was 8.5 %. CR GN and multiresistant P. aeruginosa BSIs were independent predictors of death (p = 0.002), as well as relapsed/resistant AL (18.3 %; p = 0.0002) and the presence of pulmonary infiltrates (26.6 %; p < 0.001). Although GP still predominate over GN BSI, the percentage of antibiotic resistant GN strains is considerable in AL patients and it is associated with poor prognosis.
Literatur
1.
Zurück zum Zitat Bow EJ (2009) Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 46:259–268CrossRefPubMed Bow EJ (2009) Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 46:259–268CrossRefPubMed
2.
Zurück zum Zitat Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M et al (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30(Suppl 1):S51–S59CrossRefPubMed Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M et al (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30(Suppl 1):S51–S59CrossRefPubMed
3.
Zurück zum Zitat Viscoli C, Varnier O, Machetti M (2005) Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 40(Suppl 4):S240–S245CrossRefPubMed Viscoli C, Varnier O, Machetti M (2005) Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 40(Suppl 4):S240–S245CrossRefPubMed
4.
Zurück zum Zitat Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Gonçalves VM (2003) Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center. Eur J Clin Microbiol Infect Dis 22:137–143PubMed Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Gonçalves VM (2003) Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center. Eur J Clin Microbiol Infect Dis 22:137–143PubMed
5.
Zurück zum Zitat Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110CrossRefPubMed Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110CrossRefPubMed
6.
Zurück zum Zitat Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39(Suppl 1):S25–S31CrossRefPubMed Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39(Suppl 1):S25–S31CrossRefPubMed
7.
Zurück zum Zitat Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M et al (2013) Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 19:474–479CrossRefPubMed Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M et al (2013) Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 19:474–479CrossRefPubMed
8.
Zurück zum Zitat Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C et al (2014) Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 68:321–331CrossRefPubMed Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C et al (2014) Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 68:321–331CrossRefPubMed
9.
Zurück zum Zitat Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E et al (2008) Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 61:721–728CrossRefPubMed Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E et al (2008) Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 61:721–728CrossRefPubMed
10.
Zurück zum Zitat Chong Y, Yakushiji H, Ito Y, Kamimura T (2011) Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 15:e277–e281CrossRefPubMed Chong Y, Yakushiji H, Ito Y, Kamimura T (2011) Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 15:e277–e281CrossRefPubMed
11.
Zurück zum Zitat Bow EJ (2013) There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J Antimicrob Chemother 68:492–495CrossRefPubMed Bow EJ (2013) There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J Antimicrob Chemother 68:492–495CrossRefPubMed
12.
Zurück zum Zitat Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C et al (2012) P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 91:1299–1304CrossRefPubMed Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C et al (2012) P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 91:1299–1304CrossRefPubMed
13.
Zurück zum Zitat Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R et al (2015) Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect 21:337–343CrossRefPubMed Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R et al (2015) Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect 21:337–343CrossRefPubMed
14.
Zurück zum Zitat Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C et al (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98:1826–1835CrossRefPubMedPubMedCentral Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C et al (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98:1826–1835CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F et al (2006) Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 50:498–504CrossRefPubMedPubMedCentral Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F et al (2006) Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 50:498–504CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P et al (2009) Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58:299–307CrossRefPubMed Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P et al (2009) Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58:299–307CrossRefPubMed
17.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431CrossRefPubMed Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431CrossRefPubMed
18.
Zurück zum Zitat Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP et al (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49:1–45CrossRefPubMedPubMedCentral Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP et al (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49:1–45CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281CrossRefPubMed Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281CrossRefPubMed
21.
Zurück zum Zitat Syrjälä H, Ohtonen P, Kinnunen U, Räty R, Elonen E, Nousiainen T et al (2010) Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis 29:1211–1218CrossRefPubMed Syrjälä H, Ohtonen P, Kinnunen U, Räty R, Elonen E, Nousiainen T et al (2010) Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis 29:1211–1218CrossRefPubMed
22.
Zurück zum Zitat De Rosa FG, Motta I, Audisio E, Frairia C, Busca A, Di Perri G et al (2013) Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis 13:563CrossRefPubMedPubMedCentral De Rosa FG, Motta I, Audisio E, Frairia C, Busca A, Di Perri G et al (2013) Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis 13:563CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK et al (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:794–810CrossRefPubMed Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK et al (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:794–810CrossRefPubMed
24.
Zurück zum Zitat Bow EJ (2011) Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 24:545–553CrossRefPubMed Bow EJ (2011) Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 24:545–553CrossRefPubMed
25.
Zurück zum Zitat Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 31:2810–2818CrossRefPubMed Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 31:2810–2818CrossRefPubMed
26.
Zurück zum Zitat Elting LS, Rubenstein EB, Rolston KV, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247–259CrossRefPubMed Elting LS, Rubenstein EB, Rolston KV, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247–259CrossRefPubMed
Metadaten
Titel
Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel)
verfasst von
Chiara Cattaneo
P. Zappasodi
V. Mancini
C. Annaloro
F. Pavesi
C. Skert
A. Ferrario
E. Todisco
V. Saccà
L. Verga
A. Passi
M. Da Vià
S. Ferrari
G. Mometto
M. Petullà
A. Nosari
G. Rossi
Publikationsdatum
21.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 12/2016
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2815-7

Weitere Artikel der Ausgabe 12/2016

Annals of Hematology 12/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.